Infliximab

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)3.30 [1.43, 7.61]0%3 studies28161not evaluable ROB6.05 [2.21; .]
Major congenital malformations3.11 [1.32, 7.31]0%2 studies28158not evaluable ROB5.68 [1.98; .]

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
3 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Caesarean--0 study-

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Neonatal infections4.37 [1.30, 14.71]-1 study5237not evaluable ROB8.21 [1.92; .]
Neonatal disorders (as a whole)--0 study-
Neonatal medical care--0 study-

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Intrauterine deaths (as a whole or unspecified)--0 study-
Late intrauterine deaths (> 22 weeks)--0 study-
Therapeutic terminations of pregnancy--0 study-
2 non statistically significant endpoints reported in only one study